PURPOSE OF REVIEW: To summarize the available evidence on cooccurring gastrointestinal toxicities and their potential link with other symptoms in cancer patients. The information obtained from colorectal cancer patient cohorts will be used as an example. RECENT FINDINGS: In recent years, it has become clear that gastrointestinal toxicities do not occur in isolation in cancer patients. Rather, they may link or associate with many other disturbances. Data have emerged that suggest that many of the complications of cancer chemotherapy occur in clusters and seem to support the sharing of common pathogenesis for clustering toxicities. SUMMARY: During the last few years, research in symptom clusters and cooccurring linked toxicities has markedly changed, progressively shifting from a simplistic descriptive picture to more comprehensive and pathogenetically driven analyses. Still, many questions remain to be answered, and whether and how toxicity aggregations vary during the treatment course remains to be elucidated.
PURPOSE OF REVIEW: To summarize the available evidence on cooccurring gastrointestinal toxicities and their potential link with other symptoms in cancerpatients. The information obtained from colorectal cancerpatient cohorts will be used as an example. RECENT FINDINGS: In recent years, it has become clear that gastrointestinal toxicities do not occur in isolation in cancerpatients. Rather, they may link or associate with many other disturbances. Data have emerged that suggest that many of the complications of cancer chemotherapy occur in clusters and seem to support the sharing of common pathogenesis for clustering toxicities. SUMMARY: During the last few years, research in symptom clusters and cooccurring linked toxicities has markedly changed, progressively shifting from a simplistic descriptive picture to more comprehensive and pathogenetically driven analyses. Still, many questions remain to be answered, and whether and how toxicity aggregations vary during the treatment course remains to be elucidated.
Authors: G Aprile; F E Pisa; A Follador; L Foltran; F De Pauli; M Mazzer; S Lutrino; C S Sacco; M Mansutti; G Fasola Journal: Support Care Cancer Date: 2012-06-22 Impact factor: 3.603
Authors: J M Bowen; I White; L Smith; A Tsykin; K Kristaly; S K Thompson; C S Karapetis; H Tan; P A Game; T Irvine; D J Hussey; D I Watson; D M K Keefe Journal: Support Care Cancer Date: 2015-03-27 Impact factor: 3.603
Authors: Alan Carlotto; Virginia L Hogsett; Elyse M Maiorini; Janet G Razulis; Stephen T Sonis Journal: Pharmacoeconomics Date: 2013-09 Impact factor: 4.981
Authors: Judith E Raber-Durlacher; Mike T Brennan; Irma M Verdonck-de Leeuw; Rachel J Gibson; June G Eilers; Tuomas Waltimo; Casper P Bots; Marisol Michelet; Thomas P Sollecito; Tanya S Rouleau; Aniel Sewnaik; Rene-Jean Bensadoun; Monica C Fliedner; Sol Silverman; Fred K L Spijkervet Journal: Support Care Cancer Date: 2011-12-29 Impact factor: 3.603
Authors: Sali Al-Ansari; Judith A E M Zecha; Andrei Barasch; Jan de Lange; Fred R Rozema; Judith E Raber-Durlacher Journal: Curr Oral Health Rep Date: 2015-10-19
Authors: T M Haverman; J E Raber-Durlacher; W M H Rademacher; S Vokurka; J B Epstein; C Huisman; M D Hazenberg; J J de Soet; J de Lange; F R Rozema Journal: Mediators Inflamm Date: 2014-04-10 Impact factor: 4.711